ConvaTec Group Plc stock (GB00BD3VFW73): dividend update and growth push in advanced wound care

ConvaTec Group Plc has recently confirmed its latest dividend and reiterated its focus on profitable growth in advanced wound care, ostomy care and infusion therapies, following the publication of its 2024 full?year results on March 6, 2025, according to ConvaTec full?year 2024 results as of 03/06/2025. The company reported revenue growth and updated investors on its execution against the “FISBE” strategy, while maintaining a disciplined capital allocation framework.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

ConvaTec Group Plc: core business model

ConvaTec Group Plc operates as a global medical technology company focused on chronic care and critical care solutions. Its portfolio spans ostomy care products, advanced wound care dressings, continence and critical care solutions, and infusion care sets used in a variety of clinical settings. The group mainly serves hospitals, home care providers, pharmacies and distributors worldwide, with a strong presence in both Europe and North America.

The business is designed around helping patients manage long?term conditions such as stomas, hard?to?heal wounds, incontinence and the need for safe infusion of medications. This makes ConvaTec part of the broader defensive healthcare supplies segment, where demand is often less cyclical than in many other industries. The company positions itself as a partner to healthcare systems seeking cost?effective, clinically proven products.

ConvaTec’s strategy in recent years has focused on simplifying its product portfolio, investing in innovation and strengthening commercial capabilities in key markets, including the United States. Management has also emphasized operational efficiency, with initiatives to improve manufacturing productivity and streamline the supply chain. These measures are intended to support sustainable margin expansion over the medium term.

Main revenue and product drivers for ConvaTec Group Plc

ConvaTec generates revenue across four main franchises: Advanced Wound Care, Ostomy Care, Continence & Critical Care, and Infusion Care. Growth has been particularly supported by demand for advanced wound dressings and negative pressure wound therapy solutions, which are used to treat complex and chronic wounds. According to the company’s results statement for 2024, the advanced wound care franchise delivered year?on?year revenue growth, reflecting adoption of newer technologies and increased focus on higher?value segments, as outlined in ConvaTec full?year 2024 results as of 03/06/2025.

Ostomy care remains another key profit contributor, where ConvaTec offers a wide range of ostomy appliances and accessories designed to support patients after colorectal surgeries. The franchise tends to benefit from an installed base of patients requiring ongoing supplies, which can translate into recurring revenue streams. Product renewal cycles and incremental innovations, such as skin?friendly adhesives or more discreet designs, play an important role in customer retention and pricing power.

The Continence & Critical Care franchise includes products such as urinary catheters and management systems used in intensive care units and other acute settings. Demand here is linked to hospital activity levels and demographic trends, including aging populations in developed markets. Infusion Care, which supplies infusion sets and related components, is closely tied to therapies such as insulin delivery and other chronic treatments, providing another avenue for recurring revenues.

Recent financial performance and dividend developments

On March 6, 2025, ConvaTec published its full?year 2024 results, reporting group revenue of approximately 2.35 billion USD equivalent for 2024, up year on year at constant currency, and an adjusted operating profit increase compared with 2023, according to the company’s release, which was originally presented in USD and GBP terms in the same document, as reported by ConvaTec full?year 2024 results as of 03/06/2025. The company highlighted growth across several franchises and noted progress in margin expansion despite inflationary pressures in raw materials and logistics.

In the same announcement, ConvaTec confirmed a final dividend for the 2024 financial year, continuing its progressive dividend policy. While the exact amount per share and yield depend on the share price at the time of payment, the decision signaled confidence in the underlying cash generation and balance sheet resilience. Dividend continuity tends to be closely watched by income?oriented investors who focus on healthcare names with predictable cash flows.

Cash conversion and leverage metrics also featured prominently in the 2024 update. The company reported solid free cash flow generation for 2024 and indicated that net debt to adjusted EBITDA remained within its targeted range, giving management flexibility for further investment, bolt?on acquisitions or continued shareholder returns, all according to the same full?year results communication that covered both the reporting period and publication date in March 2025.

Strategic initiatives and growth priorities

ConvaTec’s medium?term strategy continues to revolve around accelerating growth, enhancing margins and strengthening its culture and capabilities. Management has referred in past updates to its multi?year transformation program, which includes investment in research and development, digital tools for patient support, and targeted commercial initiatives in key geographies. In particular, the company has been focusing on the United States, where reimbursement frameworks and clinical practices can create attractive opportunities for advanced wound care and ostomy solutions.

Product innovation remains a key pillar of ConvaTec’s growth ambitions. The company has been launching new wound dressings, ostomy systems and catheter technologies intended to improve patient comfort, reduce complications and support better outcomes. These innovations often build on feedback from clinicians and patients, reflecting the highly specialized nature of chronic care markets. Each successful product launch can drive incremental revenue and help defend market share against competitors.

Alongside organic initiatives, ConvaTec has also shown interest in selective mergers and acquisitions to strengthen its portfolio. In recent years, the company has executed deals to expand its advanced wound care and infusion care capabilities, integrating acquired technologies and teams into its global platform. While transaction sizes have tended to be moderate, they underline a strategic preference for focused bolt?ons rather than large, transformative deals, which can carry higher integration risks.

Operational efficiency and margin focus

Operational efficiency initiatives form another important component of the ConvaTec equity story. Management has communicated plans to rationalize manufacturing sites, optimize the supply chain and standardize processes across regions, aiming to capture cost savings over time. These measures are intended to support margin improvement and free resources for reinvestment in growth projects, as described in the 2024 full?year report released in March 2025, according to ConvaTec full?year 2024 results as of 03/06/2025.

While cost optimization is important, ConvaTec also needs to maintain robust quality and regulatory compliance across its global footprint. As a manufacturer of medical products that are used directly on or in patients, the company operates under stringent regulatory frameworks in the European Union, the United States and other jurisdictions. Any major disruption in manufacturing or quality issues could affect both financial performance and reputation, which is why investments in quality systems remain a priority.

In parallel, ConvaTec continues to invest in digital tools that can improve forecasting, inventory management and customer service. Better data and analytics can help the company respond more quickly to changes in demand, reduce stockouts and optimize working capital. These operational enhancements may appear less visible than headline product launches, but they can add up to substantial improvements in profitability and cash generation over a multi?year horizon.

ESG aspects and patient impact

Environmental, social and governance considerations play a growing role in how global medical technology companies such as ConvaTec are assessed by institutional investors. The company publishes sustainability information, including targets and progress indicators, in its Annual Report and separate ESG materials, which cover topics such as product stewardship, responsible sourcing and diversity and inclusion in the workforce, as referenced in ConvaTec’s annual reporting for 2024 published in March 2025, according to ConvaTec Annual Report 2024 as of 03/06/2025.

From a social perspective, ConvaTec’s products directly influence quality of life for patients living with chronic conditions. Effective ostomy care solutions, for example, can enable patients to participate more fully in daily activities, while advanced wound dressings may reduce healing times and complications. This patient impact is often highlighted by the company in its communication with healthcare professionals and investors, as it underscores the clinical value behind its commercial models.

Governance remains another area of focus, particularly for a UK?listed company with an international shareholder base. ConvaTec’s board structure, committee oversight of risk, and approach to executive remuneration are evaluated in the context of UK corporate governance codes. Clear disclosure around these topics in the 2024 Annual Report helps investors assess alignment between management incentives and long?term value creation, as indicated in the governance section of the report published in March 2025, referenced by ConvaTec Annual Report 2024 as of 03/06/2025.

Why ConvaTec Group Plc matters for US investors

Even though ConvaTec is listed on the London Stock Exchange and reports primarily in GBP and USD, the company maintains a significant commercial footprint in the United States. Its advanced wound care and ostomy products are used by American hospitals, home health providers and patients, making the group an indirect play on US healthcare spending trends. For US?based investors who can access international markets, ConvaTec can provide exposure to the defensive healthcare supplies segment outside domestic listings.

Currency dynamics are particularly relevant for US investors considering a UK?listed stock. Fluctuations between the US dollar and the British pound can impact reported returns when holdings are translated back into USD. ConvaTec’s reporting provides both constant?currency and actual?currency figures to help investors understand underlying operational performance versus translation effects, as seen in the full?year 2024 results released in March 2025, according to ConvaTec full?year 2024 results as of 03/06/2025.

For US investors, ConvaTec also offers a way to diversify exposure within the broader medical technology landscape. Many US?listed medtech firms are heavily weighted toward capital equipment or high?end implants, whereas ConvaTec’s focus is more on chronic care consumables and advanced wound solutions. This difference in product mix can lead to distinct demand patterns across economic cycles, which is one reason why some global portfolios include both US and non?US healthcare names.

Conclusion

ConvaTec Group Plc remains a globally active medical technology company with a strong foothold in chronic care markets such as advanced wound care, ostomy care and infusion therapy. The full?year 2024 results published in March 2025 showed continued revenue growth, margin progress and a maintained dividend, suggesting a business model built around recurring demand for essential healthcare consumables. For US investors, the stock offers diversified exposure to defensive healthcare supplies outside the domestic market, albeit with additional considerations such as currency movements and UK corporate governance frameworks. As always, individual investors should weigh company?specific strengths and risks against their own objectives and risk tolerance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.